@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_head { this: np:hasAssertion dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_assertion; np:hasProvenance dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_provenance; np:hasPublicationInfo dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_publicationInfo; a np:Nanopublication . dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_assertion a np:Assertion . dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_provenance a np:Provenance . dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_publicationInfo a np:PublicationInfo . } dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_assertion { miriam-gene:390714 a ncit:C16612 . lld:C0023434 a ncit:C7057 . dgn-gda:DGNf46f0894bf22692f057ed05e5c2a0455 sio:SIO_000628 miriam-gene:390714, lld:C0023434; a sio:SIO_001121 . } dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_provenance { dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_assertion dcterms:description "[While many such markers have been proposed, few have stood the test of time; this is due to various reasons outlined in detail in this chapter.Of the reasons that have affected the usefulness and broad applicability of CLL biomarkers a few stand out as recurrent: lack of independent effects of individual markers on prognosis; the use of arbitrary cutoffs when using continuous variables; technical challenges in validity, reproducibility, and reliability (classical test characteristics); and lack of marker validation in prospectively identified CLL patient cohorts.Nonetheless, a few useful prognostic markers (CLL interphase FISH, immunoglobulin heavy chain variable region mutation status) have been identified, and others are still in transition to widespread clinical applications (TP53 mutations, SNP array-based elevated genomic complexity).As CLL therapy transitions from genotoxic combination therapies to targeted therapies, it will be of importance to reestablish the usefulness of our current understanding of individual CLL traits in CLL prognosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:24014298; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP380952.RA6hp7N6USk2A3EhUxF2cFl1CxWz3BC0ew0LeC1-wToD8130_publicationInfo { this: dcterms:created "2014-10-02T12:35:45+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }